09:46 AM EST - BriaCell Therapeutics Corp. : Announced the appointment of Giuseppe Del Priore, MD, MPH, as the Company's Chief Medical Officer (CMO), effective today. Dr. Del Priore will oversee the clinical and regulatory aspects of BriaCell’s current and upcoming clinical trials including the ongoing Phase I/IIa combination study of BriaCell’s lead candidate, Bria-IMT™, with Incyte’s checkpoint inhibitors, retifanlimab and epacadostat in advanced breast cancer. BriaCell Therapeutics Corp.
shares T.BCT are trading up $0.20 at $9.94.
